argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren's disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

argenx SE

In a report released today, Emmanuel Papadakis from Deutsche Bank downgraded arGEN X to a Hold, with a price target of €925.00. Papadakis covers th...

arGEN X (0QW0) was downgraded to a Hold Rating at Deutsche Bank

RBC Capital analyst Luca Issi maintained a Buy rating on arGEN X yesterday. The company’s shares closed last Monday at €870.00. Issi covers the Hea...

RBC Capital Keeps Their Buy Rating on arGEN X (0QW0)

In a report released today, James Gordon CFA from Barclays reiterated a Buy rating on arGEN X, with a price target of €1,000.00. According to TipRa...

Barclays Sticks to Its Buy Rating for arGEN X (0QW0)

In a report released today, Samantha Semenkow from Citi maintained a Buy rating on Argenx Se, with a price target of $1,301.00. According to TipRan...

Argenx Se (ARGX) Receives a Buy from Citi

Argenx ($ARGX) announced an update on their ongoing clinical study. The new argenx study focuses on empasiprubart in adults with multifocal motor n...

Argenx Advances Empasiprubart in Rare Nerve Disorder, Adding Long-Term Upside for ARGX Investors

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Argenx Se (ARGX), NeoGenomics (NEO) and Repligen (RG...

Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), NeoGenomics (NEO)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Baxter International (BAX), Incyte (INCY) and Arge...

Analysts Conflicted on These Healthcare Names: Baxter International (BAX), Incyte (INCY) and Argenx Se (ARGX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Demant (WILLF), Argenx Se (ARGX) and Capricor Therap...

Analysts Are Bullish on These Healthcare Stocks: Demant (WILLF), Argenx Se (ARGX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Argenx Se (ARGX) and Omeros (OMER). Argenx Se (ARG...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ARGX	$1,021.04	+0.98%	40.17K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ARGX	$1,021.04	+1.0%	40.17K
3
4
5
6

ARGX

Get argenx SE Data in Excel

Get argenx SE Data in Excel